International Nosocomial Infection Control Consortium report, data summary for 2002-2007, issued January 2008
AuthorsRosenthal, Víctor Daniel
Maki, Dennis George
Álvarez-Moreno, Carlos Arturo
Cuellar, Luis E.
Navoa-Ng, Josephine Anne
Guanche Garcell, Humberto
Medeiros, Eduardo A.
Kanj, Souha S.
Diez Pratesi, Ricardo
International Nosocomial Infection Control Consortium Members
Pontificia Universidad Javeriana. Facultad de Medicina. Departamento de Medicina Interna. Grupo de Investigación en Enfermedades Infecciosas HUSI - PUJ
Artículo de revista
0196-6553 / 1527-3296 (Electrónico)
Share this record
MetadataShow full item record
We report the results of an International Nosocomial Infection Control Consortium (INICC) surveillance study from 2002 through 2007 in 98 intensive care units (ICUs) in Latin America, Asia, Africa, and Europe. During the 6-year study, using Centers for Disease Control and Prevention (CDC) National Nosocomial Infections Surveillance System (NNIS) definitions for device-associated health care-associated infection, we collected prospective data from 43,114 patients hospitalized in the Consortium's hospital ICUs for an aggregate of 272,279 days. Although device utilization in the INICC ICUs was remarkably similar to that reported from US ICUs in the CDC's National Healthcare Safety Network, rates of device-associated nosocomial infection were markedly higher in the ICUs of the INICC hospitals: the pooled rate of central line–associated bloodstream infections (CLABs) in the INICC ICUs, 9.2 per 1000 CL-days, is nearly 3-fold higher than the 2.4–5.3 per 1000 CL-days reported from comparable US ICUs, and the overall rate of ventilator-associated pneumonia was also far higher, 19.5 vs 1.1–3.6 per 1000 ventilator-days, as was the rate of catheter-associated urinary tract infection, 6.5 versus 3.4–5.2 per 1000 catheter-days. Most strikingly, the frequencies of resistance of Staphylococcus aureus isolates to methicillin (MRSA) (80.8% vs 48.1%), Enterobacter species to ceftriaxone (50.8% vs 17.8%), and Pseudomonas aeruginosa to fluoroquinolones (52.4% vs 29.1%) were also far higher in the Consortium's ICUs, and the crude unadjusted excess mortalities of device-related infections ranged from 14.3% (CLABs) to 27.5% (ventilator-associated pneumonia).
Link to the resourcehttps://www-clinicalkey-es.ezproxy.javeriana.edu.co/#!/content/journal/1-s2.0-S0196655308001661
SourceAmerican Journal of Infection Control; Vol. 36 Núm.9 (2008)
- Artículos